Vibsane-type diterpenoids from Viburnum odoratissimum inhibit hepatocellular carcinoma cells via the PI3K/AKT pathway

被引:9
作者
Xue, Xiao-Bian [1 ]
Lv, Tian-Ming [1 ]
Hou, Jiao-Yang [1 ]
Li, Dan-Qi [2 ]
Huang, Xiao-Xiao [1 ]
Song, Shao-Jiang [1 ]
Yao, Guo-Dong [1 ]
机构
[1] Shenyang Pharmaceut Univ, Engn Res Ctr Nat Med Act Mol Res & Dev, Sch Tradit Chinese Mat Med, Key Lab Computat Chem Based Nat Antitumor Drug Res, Shenyang 110016, Liaoning, Peoples R China
[2] Shenyang Univ Chem Technol, Inst Funct Mol, Shenyang 110142, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; Viburnum odoratissimum; Vibsane-type diterpenoids; PI3K/AKT pathway; SORAFENIB; MODULATION;
D O I
10.1016/j.phymed.2022.154499
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with an elevated danger of metastasis and a short survival rate. Vibsane-type diterpenoids with novel structures possess marked antitumor activities against multiple cancer cells. However, the exact mechanism is poorly unclear. Purpose: To assess the antitumor mechanism of vibsane-type diterpenoids derived from Viburnum odoratissimum (V. odoratissimum) against HCC cells in vitro and in vivo. Methods: The main constituents in the ethyl acetate extract of V. odoratissimum (EAVO) were identified by LC-MS/MS. The antiproliferative activity of EAVO in vitro was evaluated by MTT assays. Annexin V-FITC/PI, AO/EB, and Hoechst 33,258 staining were employed to detect apoptosis. JC-1 fluorescence dye was used to detect the mitochondrial membrane potential (MMP). The levels of intracellular ROS and mitochondrial superoxides were assessed by H2DCF-DA and MitoSox staining, respectively. The levels of oxidative stress were determined by ROS Green (TM) H2O2 probe, hydroxyphenyl fluorescein (HPF), and the C11 BODIPY 581/591 fluorescent probe. Transcriptomics was performed to investigate the antitumor mechanism of EAVO in HCC. The molecular mechanism by which EAVO suppressed HCC cells was verified by Western blot, RT-PCR, and HTRF (R) KinEASE (TM)-STK S3 kits. The efficacy and safety of EAVO in vivo were evaluated using Hep3B xenograft models. Results: Vibsane-type diterpenoids were the main constituents of EAVO by LC-MS/MS. EAVO suppressed proliferation, aggravated oxidative stress, and promoted apoptosis in HCC cells. Moreover, EAVO dramatically inhibited tumor growth in Hep3B xenograft models. Transcriptomics results indicated that EAVO inhibited HCC cell proliferation by regulating the PI3K/AKT pathway. Vibsanin B, vibsanol I, and vibsanin S isolated from EAVO was used to further verify the antitumor activity of vibsane-type diterpenoids subsequently. Interestingly, the kinase results showed that vibsanin B and vibsanol I exhibited vital AKT kinase inhibitory activities. Conclusions: Collectively, this study provided a comprehensive mechanism overview of vibsane-type diterpenoids against HCC cells in vitro and in vivo. It also laid a foundation for further antitumor investigation of vibsane-type diterpenoids in V. odoratissimum.
引用
收藏
页数:14
相关论文
共 50 条
[31]   Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway [J].
Wang, Li ;
Yang, Huiyu ;
Wang, Chen ;
Shi, Xiaoxin ;
Li, Kunkun .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 120
[32]   Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma [J].
Liu, Ting ;
Xie, Xiao-Li ;
Zhou, Xue ;
Chen, Sheng-Xiong ;
Wang, Yi-Jun ;
Shi, Lin-Ping ;
Chen, Shu-Jia ;
Wang, Yong-Juan ;
Wang, Shu-Ling ;
Zhang, Jiu-Na ;
Dou, Shi-Ying ;
Jiang, Xiao-Yu ;
Cui, Ruo-Lin ;
Jiang, Hui-Qing .
WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (28) :4667-4686
[33]   Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway (vol 17, pg 626, 2022) [J].
Huang, Lu ;
Yang, Qiong ;
Chen, Huihong ;
Wang, Zhenggeng ;
Liu, Qi ;
Ai, Shuhua .
OPEN MEDICINE, 2022, 17 (01) :1065-1065
[34]   Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway [J].
Liu, Hong-Yuan ;
Dong, Tian-Xiu ;
Li, Zi-Zhuo ;
Li, Tian-Tian ;
Jiang, Jian ;
Zhu, Ming-Wei ;
An, Ting-Ting ;
Chen, Yao-Dong ;
Yang, Xiu-Hua .
NEOPLASMA, 2021, 68 (05) :924-937
[35]   CD276 Promotes Vasculogenic Mimicry Formation in Hepatocellular Carcinoma via the PI3K/AKT/MMPs Pathway [J].
Cheng, Rui ;
Wang, Bi ;
Cai, Xin-ran ;
Chen, Zhi-shan ;
Du, Qiang ;
Zhou, Liang-yi ;
Ye, Jing-min ;
Chen, Yan-ling .
ONCOTARGETS AND THERAPY, 2020, 13 :11485-11498
[36]   ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro [J].
Song, Lei ;
Luo, Yi ;
Li, Shaoling ;
Hong, Ming ;
Wang, Qi ;
Chi, Xiaoling ;
Yang, Cong .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 :4363-4376
[37]   Limonin provokes hepatocellular carcinoma cells with stemness entry into cycle via activating PI3K/Akt signaling [J].
Tang, Zhenyong ;
Tang, Yuntian ;
Li, Lei ;
Liu, Tianqi ;
Yang, Jianrong .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
[38]   The role of PI3K/AKT signaling pathway in gallbladder carcinoma [J].
Wu, Zeyu ;
Yu, Xiao ;
Zhang, Shuijun ;
He, Yuting ;
Guo, Wenzhi .
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (07) :4426-4442
[39]   APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target [J].
Chen, Huarong ;
Wong, Chi-Chun ;
Liu, Dabin ;
Go, Minnie Y. Y. ;
Wu, Bin ;
Peng, Sui ;
Kuang, Ming ;
Wong, Nathalie ;
Yu, Jun .
THERANOSTICS, 2019, 9 (18) :5246-5260
[40]   FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells [J].
Liu, Huayuan ;
Zhao, Lei ;
Wang, Mengya ;
Yang, Kexin ;
Jin, Zhipeng ;
Zhao, Chengjian ;
Shi, Guangjun .
FRONTIERS IN ONCOLOGY, 2022, 12